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molecular drug-susceptibilityCross-resistance in rifamycins has been observed in rifampin (RIF)-resistantMycobacterium tuberculosis complex
isolates; some rpoB mutations do not confer broad in vitro rifamycin resistance. We examined 164 isolates, of
which 102 were RIF-resistant, for differential resistance between RIF and rifabutin (RFB). A total of 42 unique
single mutations or combinations of mutations were detected. The number of unique mutations identiﬁed
exceeded that reported in any previous study. RFB and RIF MICs up to 8 μg/mL by MGIT 960 were studied; the
cut-off values for susceptibility to RIF and RFBwere 1 μg/mL and 0.5 μg/mL, respectively.We identiﬁed 31 isolates
resistant to RIF but susceptible to RFB with the mutations D516V, D516F, 518 deletion, S522L, H526A, H526C,
H526G, H526L, and two dual mutations (S522L + K527R and H526S + K527R). Clinical investigations using
RFB to treat multidrug-resistant tuberculosis cases harboring those mutations are recommended.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multidrug-resistant tuberculosis (MDR-TB), deﬁned as disease
caused by strains of Mycobacterium tuberculosis complex (MTBC) that
are resistant to isoniazid and rifampin (RIF), is a major obstacle to the
treatment and control of TB globally (World Health Organization,
2010). The concern over MDR-TB has necessitated not only initiatives
to improve diagnostic testing capabilities and more efﬁcient detection
of drug resistance; it has also prompted a search for alternative drug op-
tions for treating MDR-TB. Rifamycin drugs are generally very effective
against MTBC, with RIF serving as an important primary drug in the
treatment arsenal for TB. Another drug in this class, rifabutin (RFB),
has fewer interactions with protease inhibitor drugs compared to RIF.
It is often used to treat Mycobacterium avium complex and MTC in
HIV-infected patients but is not commonly used as a ﬁrst-line treatment
for TB. Although the effectiveness of RFB in treating patients with drug-
susceptible TB has been demonstrated, documentation of successful
treatment ofMDR-TB patients with RFB, even in patients whose isolatesASM General Meeting in San
1-650-573-2147.
ealth Public Health Laboratory,
anton, CA.
nt Public Health Laboratory,
. This is an open access article underare susceptible in vitro to RFB, is limited (Aristoff et al., 2010; Davies
et al., 2007; Gillespie et al., 1990; Horne et al., 2011). This may partly
be due to general concerns about potential cross-resistance among the
rifamycins and the fact that clinical efﬁcacy of RFB for treatment of
RIF-resistant strains in MDR-TB patients has not yet been well-
established (Aristoff et al., 2010; García et al., 2010; Luna-Herrera
et al., 1995; Uzun et al., 2002; van den Boogaard et al., 2009; Van
Ingen et al., 2011).
Certain mutations in the RIF resistance determining region (RRDR)
of the rpoB gene of MTBC appear to confer cross-resistance to both RIF
and RFB (Anthony et al., 2005; Bodmer et al., 1995; Cavusoglu et al.,
2004; Chen et al., 2012; Jamieson et al., 2014; Sintchenko et al., 1999;
Tan et al., 2012; Van Ingen et al., 2010; Williams et al., 1998; Yang
et al., 1998; Yoshida et al., 2010). The mutations S531L, H526Y and
H526D are most common and are found in isolates from a majority of
MDR-TB patients. However, RIF-resistant strains possessing certainmu-
tations, mostly in codons 511, 516, 518, 522, 526, 533, may retain a level
of in vitro susceptibility to RFB depending on the particular amino acid
substitutions and have the potential to be clinically effective against
RIF-resistant MTBC strains (Anthony et al., 2005; Bodmer et al., 1995;
Cavusoglu et al., 2004; Chen et al., 2012; Jamieson et al., 2014;
Sintchenko et al., 1999; Tan et al., 2012; Van Ingen et al., 2010;Williams
et al., 1998; Yang et al., 1998; Yoshida et al., 2010). Utilization of molec-
ular assays capable of discriminating single nucleotide polymorphism
(SNPs) in the RRDR at the nucleotide level may allow for the prediction
of culture-based drug susceptibility testing (CDST) results to RIF and
RFB (Chen et al., 2012; Halse et al., 2010; Jamieson et al., 2014; Linthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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use of molecular diagnostics for detection of RIF resistance, an under-
standing of the relationship between different rpoB mutations and
their associationwith differential resistance levels may be helpful to cli-
nicians treating RIF-resistant TB or MDR-TB as a real-time complement
to CDST which can take weeks to be completed.
While determination of RIF and RFB MICs in association with rpoB
mutations has been investigated, most of those studies included either
relatively low numbers of isolates or commonly encounteredmutations
(Anthony et al., 2005; Bodmer et al., 1995; Cavusoglu et al., 2004; Chen
et al., 2012; Jamieson et al., 2014; Sintchenko et al., 1999; Van Ingen
et al., 2010; Williams et al., 1998; Yang et al., 1998; Yoshida et al.,
2010). California has the most TB and MDR-TB cases in the US. Our
laboratory has used molecular methods to test clinical specimens or
cultures for drug resistance mutations including those in RRDR since
2003. We have found that rpoB mutations are associated with a wide
range of RIF MICs and that not all rpoBmutations confer RIF resistance
as measured by a liquid culture-based standard phenotypic DST
method, MGIT 960 (Becton Dickinson Diagnostic Systems, Sparks, MD,
USA). In this study, we determined RFB and RIF MICs using MGIT 960
on isolates with various rpoB mutations from our archived collection.
All theMIC datawere generated by the same CDSTmethod and allowed
a head-to-head comparison of the effect of a mutation on MIC changes
for the two drugs. The goal of this study is to strengthen our under-
standing of and conﬁdence in the role of rpoBmutations in differential
resistance to RIF and RFB, and to lay a foundation for building a diverse
collection of genotype/phenotype data to support the establishment of
clinical trials to determine if the observed in vitro differential resistance
can be used to guide treatment.
2. Materials and methods
2.1. Bacterial isolates
A total of 164 MTBC isolates (102 RIF-resistant and 62 RIF-
susceptible) were included in the study. Of the 102 RIF-resistant iso-
lates, 71 were from TB patients from California (including many global
immigrants) and 31 were contributed by India (Mumbai), Philippines
(Manila) and across South Africa and Moldova through the Global
Consortium for Drug-resistant TB Diagnostics (GCDD) (Hillery et al.,
2014). RIF-resistant isolates were selected to include a wide variety of
rpoB mutations as determined by a well-established pyrosequencing
assay (Lin et al., 2014); 41 of them with known RFB results previously
determined by the agar proportion.We randomly selected 42 susceptible
strains that had wild-type rpoB sequences. We also included 20 strains
which had rpoBmutations but tested RIF-susceptible by MGIT 960.
2.2. Drug solutions
RFB was obtained from Sigma-Aldrich (St. Louis, MO, USA) and US
Pharmacopeia (Rockville, MD, USA), and RIF from US Pharmacopeia.
The drugs were dissolved in HPLC-grade absolute methanol into
16-μg/mL or 32-μg/mL stock solutions for RFB and RIF, respectively,
and then ﬁlter-sterilized using 0.22 μm ﬁlters (VWR). The stock solutions
were aliquoted in small volumes and stored at−70 °C. The 8 μg/mL con-
centration was diluted in methanol from the stock solution, and the
lower concentrations were made in sterile, deionized water for both
drugs. These dilutions were frozen at−20 °C in small aliquots for future
use, and they were limited to three freeze-thaw cycles before being
discarded. All the concentrations were expressed as the test
concentrations with MGIT 960.
2.3. Testing for MIC
MICs of RIF and RFB were determined by MGIT 960. Isolates were
sub-cultured onto Löwenstein-Jensen (LJ) slants (Becton Dickinson,Sparks, MD, USA) and used for testing within 4 weeks of inoculation.
The manufacturer’s instructions for testing primary drugs of isolates
growing on solid media were followed with a modiﬁcation. Instead of
a 1:5 dilution, a 1:3 dilution of the cell suspension equivalent to the
0.5 McFarland standard was used to inoculate the drug-containing
MGIT. This modiﬁcation yielded a 100% correlation with a 15 to 24 h
shortened turnaround time when compared with the unmodiﬁed pro-
cedure (unpublished data). All 164 isolates were tested for RFB MICs
from 0.0625 to 8 μg/mL. We also tested RIF MIC from 0.125 to 8 μg/mL
on a subset of 91 isolates from the 164 isolates; 87 isolates comprised
of strains with representative rpoB mutations and 4 isolates were of
wild-type rpoB sequence. As there is no publishedWHO critical concen-
tration for determiningwhether an isolate is “resistant” to RFB, we used
a breakpoint concentration of 0.5 μg/mL, as suggested inmultiple previ-
ous studies (Cavusoglu et al., 2004; Clinical Laboratory Standards Insti-
tute, 2011; Heifets et al., 1998; Krüüner et al., 2006; Pfyffer et al., 1999;
Rüsch-Gerdes et al., 2006). The critical concentration for RIF was 1.0
μg/mL, as permanufacturer’s protocol and theWHO published standard
(Clinical Laboratory Standards Institute, 2011; World Health Organiza-
tion, 2008).
2.4. Pyrosequencing
The rpoB sequence from codons 507 to 533was determined for each
isolate by pyrosequencing. It was performed as described previously
(Lin et al., 2014) using the Qiagen PyroMark Q96 ID system (Qiagen,
Valencia, CA, USA).
2.5. Quality control (QC)
For the QC strain ofM. tuberculosis, H37Rv (ATCC 27294), MIC of RIF
was tested from 0.0625 to 0.5 μg/mL and that of RFB was tested from
0.0312 to 0.125 μg/mL for each batch of CDST or once a week if more
than one run was performed. This was to assess drug performance
with each drug dilution lot and to demonstrate that the potency of RIF
and RFB was maintained properly during the study. For the QC of pyro-
sequencing, the QC reference strain and PCR-gradewaterwere included
in each run. If the expected values for the controls were not obtained,
the test run was repeated.
3. Results
3.1. Determination of the RRDR sequences
The rpoB gene of all isolates was successfully sequenced from codon
507 through 533 using pyrosequencing. We identiﬁed a total of 42 mu-
tations including 24 unique single nucleotide substitutions, three dele-
tions involving single or multiple codons, 14 multiple mutations and
one synonymous mutations (Table 1). The 31 isolates from global
sources contributed 13 unique mutations; ﬁve of them were new to
our laboratory including the H526Cmutation and 4 other mutations in-
volving multiple codons. Of the 42 mutations, 24 (57%) were not found
in the TB Drug Resistance Mutation Database (www.tbdreamdb.com)
(Sandgren et al., 2009), although we were unable to verify if all of
them were novel mutations. In addition, there were 42 RIF-susceptible
isolates with wildtype sequences that were exact matches to the
QC strain.
3.2. RIF and RFB MICs of the QC strain
We tested the RIF MIC for the QC strain with the same cell suspen-
sion in parallel using RIF from the MGIT 960 SIRE kit (Becton Dickinson
Diagnostic Systems, Sparks, MD) and from US Pharmacopeia to ensure
the RIF powder from US Pharmacopeia would perform equally with
the RIF from the MGIT 960 SIRE kit, which is routinely used with MGIT
960. We found RIF MIC consistently tested at 0.125 μg/mL for the QC
Table 1
Observed MIC for RFB and RIF and associated rpoBmutations.
Amino acid change (nucleotide changes) Observed MIC (μg/mL)
RIF MIC (Isolates tested) RFB MIC (Isolates tested)
Group I, RIF-S and RFB-S
Wildtype ≤0.125 (2), 0.125 (2) ≤0.0625 (37), 0.125 (5)
L511P (CCG) ≤0.25 (2), 0.25 (1) ≤0.0625 (2), 0.0625 (1)
F514F (TTT) 0.125 (2) ≤0.0625 (2)
D516Y (TAC) 0.25 (2), 0.5 (2) 0.0625 (4)
H526N (AAC) 0.125 (2), 0.25 (1) ≤0.0625 (2), 0.125 (1)
H526S (AGC) 0.5 (1), 1 (1) ≤0.0625 (1), 0.125 (1)
H526S (TCC) 0.25 (1) ≤0.0625 (1)
S531C (TGT) ≤0.125 (1) 0.0625 (1)
L533P (CCG) 0.5 (2) 0.125 (1), 0.25 (1)
T508 to S509 deletion 0.5 (1) ≤0.0625 (1)
M515I (ATA) + H526N (AAC) 1 (1) 0.125 (1)
Group II, RIF-R and RFB-S
D516V (GTC) 8 (3), N8 (15) 0.125 (2), 0.25 (6), 0.5 (10)
D516F (TTC) 2 (1) 0.0625 (1)
S522L (TTG) 2 (1) 0.0625 (1)
H526A (GCC) 2 (1) 0.125 (1)
H526C (TGC) 2 (1), 8 (1) 0.125 (2)
H526G (GGC) 2 (1) 0.125 (1)
H526L (CTC) 2 (2), 4 (1), 8 (1) 0.125 (2), 0.25 (1), 0.5 (1)
N518 deletion 4 (1) 0.125 (1)
S522L (TTG) + K527R (AGG) 8 (1) 0.5 (1)
H526S (TCC) + K527R (CGG) 4 (1) 0.25 (1)
Group III, RIF-R AND RFB-R
Q513E (GAA) N8 (2) 1 (2)
Q513K (AAA) N8 (3) N8 (3)
Q513L (CTA) N8 (1) N8 (1)
Q513P (CCA) N8 (2) 1 (1), 2 (1)
H526D (GAC) N8 (3) 8 (2), N8 (1)
G526R (CGC) N8 (2)a 8 (2), N8 (3)
H526Y (TAC) N8 (1)a 8 (2), N8 (2)
S531F (TTC) N8 (1) N8 (1)
S531W (TGG) N8 (3)a 4 (1), 8 (2), N8 (1)
S531L (TTG) N8 (5)a 2 (7), 4 (25), 8 (1)
S509R (CGC) + H526Y (TAC) N8 (1) 8 (1)
S509R (AGG) + H526L (CTC) N8 (1) 8 (1)
Q510L (CTG) + D516V (GTC) N8 (1) 1 (1)
L511P (CCG) + S512T (ACC) + D516Y (TAC) N8 (1) 8 (1)
L511P (CCG + D516Y (TAC) N8 (2) 2 (2)
Q513L (CTA) + H526N (AAC) N8 (1) N8 (1)
F514F (TTT) + S531L (TTG) N8 (1) 8 (1)
515–521 deletion N8 (1) 8 (1)
D516E (GAG) + S522L (TTG) N8 (1) 1 (1)
D516V (GTC) + S531L (TTG) N8 (1) 4 (1)
D516G (GGC) + L533P (CCG) N8 (1) 4 (1)
H526Q (CAG) + L533P (CCG) N8 (1) 1 (1)
a Thesemutations are commonly found in isolates fromMDR TB patients and they are known to confer high level resistance to RIF; RIFMICwas performed for limited numbers of those
strains. RFB MIC was performed for all strains included in this study.
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QC strain using RFB from two different sources and found the RFB MIC
tested consistently at 0.0312 to 0.0625 μg/mL.3.3. RIF and RFB MICs and the association with RRDR mutations
Table 1 shows the results of MIC tested byMGIT 960 for RIF and RFB.
Overall the observedMICswere considered narrow.Wenoticed RIFMIC
range appeared to be wider for isolates with 526C and 526L mutations;
similarly RFBMICs rangewaswiderwith isolates having 516V and 531L
mutations. However, the variability of these MICs was still within plus/
minus one 2-fold dilution of themeanMIC.We categorized isolates into
3 groups. Group 1 isolates were susceptible to both RIF and RFB, group 2
isolates were resistant to RIF but susceptible to RFB, and group 3 isolates
were resistant to both RIF and RFB. For group 1, RIFMICswere 0.125 to 1
μg/mL and RFB MICs were ≤0.0625 μg/mL to 0.25 μg/mL. Besides the 42
isolateswithwildtype rpoB sequence,we found 20 isolates harboring 10
unique mutations were also in this group: a synonymous mutation, 7mis-sense mutations [L511P, D516Y, H526N, H526S (nucleotide chang-
es of AGC and TCC), S531C, L533P], a deletion of codons 508–509 and a
dual mutation of M515I and H526N. For group 2, the RIFMICs were 2 to
≥8 μg/mL and RFB MICs were 0.0625–0.5 μg/mL. The most frequently
detected mutation in this group was D516V; nine other mutations de-
tected were D516F, S522L, H526A, H526C, H526G, H526L, codon 518
deletion and two dual mutations (S522L plus L527R, and H526S plus
L527R). For group 3, the RIF and RFB MICs were N8 μg/mL and 1 to N8
μg/mL, respectively. The most common mutation found in MDR-TB
cases was S531L. Additional 22 mutations detected were Q513E,
Q513K, Q513L, Q513P, N519K, H526D, H526R, H526Y, S531F, S531W,
2 multiple codon deletion and 11 multiple mutations (Table 1).4. Discussion
We detected 42 different rpoBmutations from a total of 164 strains
studied, representing a wide variety of mutations including 24 infre-
quently encountered single or multiple mutations that have not been
180 Z.L. Berrada et al. / Diagnostic Microbiology and Infectious Disease 85 (2016) 177–181listed in the TB Drug Resistance Mutation database to date. Our study
demonstrated the association of various RRDR mutations with the dif-
ferential expression of phenotypic resistance or susceptibility to RIF
and RFB as measured by MGIT 960. These data may serve as a starting
point to establish a database containingMIC values of RFB and RIF asso-
ciatedwith speciﬁc rpoBmutations, whichwill evolve as newmutations
are detected and newMIC values added. The need for establishing such
a database connecting results of molecular drug susceptibility (MDST)
and CDST has been suggested in recent publications (Lin & Desmond,
2014; Salamon et al., 2015) and is critical to the formulation of trial
treatment regimens based on rapidly detectable genotypes and predict-
ed phenotypes. The inclusion of a relatively large number of RIF-
resistant strains and the diversity of mutations we observed is a signif-
icant contribution to the growing body of knowledge suggesting certain
rpoBmutations are associated with differential RIF/RFB resistance.
Guidelines for using MGIT 960 to test second-line antituberculous
drugs are available (Clinical Laboratory Standards Institute, 2011; World
Health Organization, 2008). Testing RFB by MGIT 960 using 0.5 μg/mL as
a breakpoint concentration for interpreting RFB susceptibility results has
been demonstrated in multiple studies (Krüüner et al., 2006; Rüsch-
Gerdes et al., 2006) to perform comparably to the BACTEC 460 (Pfyffer
et al., 1999) and agar proportionmethods. In this study,we demonstrated
that the breakpoint of 0.5 μg/mL was at least 4-fold higher than MICs for
wild-type isolates (RIF-susceptible with no rpoBmutations). These data
are consistent with previous studies and support use of this breakpoint
withMGIT960 todetect in vitroRFB-resistance.While this breakpoint suf-
ﬁciently distinguishes wild-type isolates from those with rpoBmutations
that confer RIF and RFB cross-resistance in vitro, establishment of a critical
concentration that can reliably guide effective therapy, especially in in-
stances where some level of RIF resistance is determined, should ideally
incorporate additional information obtained through clinical and phar-
macological studies (Schön et al., 2013).
From the RFB and RIFMIC data generated in this study, we observed
42 distinct rpoB mutations. Twenty (48%) of these 42 rpoB mutations
(Group 1 and Group 2 combined)were associatedwith in vitro RFB sus-
ceptibility. This suggests that RFB may have clinical efﬁcacy in patients
with isolates harboring these differential resistance mutations (Sirgel
et al., 2013), although the frequency of isolates possessing these muta-
tions was far lower than those, such as S531L, found in most MDR-TB
patients. These ﬁndings and similar ﬁndings in other studies demon-
strate SNP-speciﬁc differential phenotypic resistance to the various
drugs within a class of drugs such as rifamycins and ﬂuoroquinolones
(Bernard et al., 2015). They also highlight the advantage of using
sequence-basedmolecularmethods,which provide themutation identity
when a mutation is detected, in preference to probe-based methods; the
latter either do not identify individual SNPs (such asGeneXpert’sMTB/RIF
assay) or only identify few common mutations (such as HAIN or INNO-
LIPA line-probe assays). As evidence accumulates for the added value of
rapid SNP-speciﬁc phenotypic predictions, sequence-based MDST
methodsmayhave signiﬁcant clinical advantages (Lin&Desmond, 2014).
We also tested isolates with so called “disputed” mutations, such as
L511P, D516Y, H526N, H526S, S531C, L533P, S522TTG and H526L,
which have been reported to confer highly discordant RIF results by
CDST (Rigouts et al., 2013; Van Deun et al., 2009, 2013). Due to concerns
over failure to detect phenotypic RIF-resistance by MGIT 960 in isolates
harboring these disputed mutations, a consideration of lowering the crit-
ical concentration of RIF to bring rpoB genotype and phenotype into con-
cordance has been discussed. However, as shown in our study, RIF MICs
associated with those disputed mutations, except for S522L and H526L,
either overlapped with that of the wildtype strains or were only slightly
increased. Lowering the critical concentration of RIF to 0.5 μg/mLwill im-
prove our detection of these strains, but will not allow us to detect all of
them. Yet the risk of generating false RIF-resistancemay be increased be-
cause the critical concentration is close to the MIC of wildtype strains.
False RIF-resistancemay cause removal of RIF from regimens and adverse
impacts on TB patient management may ensue.In conclusion, our study demonstrated that various rpoBmutations
were associated with differential RIF and RFB susceptibility or resis-
tance. The accumulated information on RRDRmutations and the associ-
ated RIF and RFBMICs deepens our conﬁdence in the potential for using
MDST to rapidly predict CDST results several weeks before those results
are typically available. However, while our data suggest the clinical po-
tential of using RFB for treating patients whose isolates contain rpoB
mutations associated with in vitro RFB susceptibility, clinical investiga-
tions are required to verify that RFB can be used effectively in these pa-
tients to improve outcomes.
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